Acun G, Ozdemir H, Sunamak O, Unal OZ, Baskan E, Yazi M, Savas B, Berberoglu U

Idioma: Ingles.
Referencias bibliográficas: 30
Paginas: 279-284
Archivo PDF: 185.21 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. ten Broek RP, Bakkum EA, Laarhoven CJ, van Goor H Epidemiology and prevention of postsurgical adhesions revisited. Ann Surg. 2016;263:12-9.

2. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions; etiology, pathophysiology, and clinical significance. Dig Surg. 2001;18:260-73.

3. Morawski B, Nawrot I, Klonowski W, Mądrecki M, Tarnowski W. Peritoneal adhesions as a cause of mechanical small bowel obstruction based on own experience. Pol Przegl Chir. 2015;86: 523-31.

4. Arung W, Meurisse M, Detry O. Pathophysiology and prevention of postoperative peritoneal adhesions. World J Gastroenterol. 2011;17:4545-53.

5. Makarchian HR, Kasraianfard A, Ghaderzadeh P, Javadi SM, Ghorbanpoor M. The effectiveness of heparin, platelet-rich plasma (PRP), and silver nanoparticles on prevention of postoperative peritoneal adhesion formation in rats. Acta Cir Bras. 2017;32:22-7.

6. Cassidy MR, Sheldon HK, Gainsbury ML, et al. The neurokinin 1 receptor regulates peritoneal fibrinolytic activity and postoperative adhesion formation. J Surg Res. 2014;191:12-8.

7. Giusto G, Beretta G, Vercelli C, et al. A pectin-honey hydrogel prevents postoperative intraperitoneal adhesions in a rat model. BMC Vet Res. 2017;13:55.

8. De Clercq K, Schelfhout C, Bracke M, et al. Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: in vitro and in vivo characterization. Biomaterials. 2016;96:33-46.

9. Poehnert D, Grethe L, Maegel L, et al. Evaluation of the effectiveness of peritoneal adhesion prevention devices in a rat model. Int J Med Sci. 2016;13:524-32.

10. Diamond MP, El-Hammady E, Munkarah A, Bieber EJ, Saed G. Modulation of the expression of vascular endothelial growth factor in human fibroblasts. Fertil Steril. 2005;83:405-9.

11. Kalofonos HP, Grivas PD. Monoclonal antibodies in the management of solid tumors. Curr Top Med Chem. 2006;6: 1687-705.

12. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-50.

13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.

14. Chiang SC, Cheng CH, Moulton KS, Kasznica JM, Moulton SL. TNP-470 inhibits intraabdominal adhesion formation. J Pediatr Surg. 2000;35:189-96.

15. Greene AK, Alwayn IP, Nose V, et al. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg. 2005;242:140-6.

16. Ignjatovic D, Aasland K, Pettersen M, et al. Intra- abdominal administration of bevacizumab diminishes intra-peritoneal adhesions. Am J Surg. 2010;200:270-5.

17. Zuhlke HV, Lorenz EM, Straub EM, Savvas V. Pathophysiology and classification of adhesions. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990;1:1009-16.

18. Fredriksson F, Sellberg F, Bowden T, Engstrand T, Berglund D, Lilja HE. Sutures impregnated with carbazate-activated polyvinyl alcohol reduce intraperitoneal adhesions. J Pediatr Surg. 2017;52:1853-8.

19. Brochhausen C, Schmitt VH, Mamilos A,et al. Expression of CD68 positive macrophages in the use of different barrier materials to prevent peritoneal adhesions-an animal study. J Mater Sci Mater Med. 2017;28:15.

20. Koninckx PR, Gomel V. Introduction: quality of pelvic surgery and postoperative adhesions. Fertil Steril. 2016;106:991-3.

21. Conze J, Junge K, Klinge U, et al. Intraabdominal adhesion formation of polyprolene mesh. Influence of coverage of omentum and polyglactin. Surg Endosc. 2005;19:798-803.

22. Bikfalvi A. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/ VEGFR system. Biochem Pharmacol. 2004;68:1017-21.

23. Costache MI, Iordache S, Costache CA, Dragos E, Dragos A, Saftoiu A. Molecular analysis of vascular endothelial growth factor (VEGF) receptors in EUS-guided samples obtained from patients with pancreatic adenocarcinoma. J Gastrointestin Liver Dis. 2017;26:51-7.

24. Beddy D, Watson RW, Fitzpatrick JM, O’Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn’s disease. Br J Surg. 2004;91:72-7.

25. Henry CR, Sisk RA, Tzu JH, et al. Long-term follow-up of intravitreal bevacizumab for the treatment of pediatric retinal and choroidal diseases. JAAPOS. 2015;19:541-8.

26. Wang JK, Su PY, Hsu YR, Chen YJ, Chen FT, Tseng YY. Comparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusion. J Ophthalmol. 2016;2016:8421940.

27. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69:25-33.

28. Moraloglu O, Işik H, Kiliç S, et al. Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertil Steril. 2011; 95:2638-41.

29. Jordan K, Luetkens T, Gog C, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebocontrolled phase II study-AIO SUP-0108. Eur J Cancer. 2016;63:127-34.

30. Maggiore UL, Bellati F, Ruscito I, et al. Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther. 2013;13: 739-64.